|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
11 March 2024 |
|
Main ID: |
NCT03775174 |
|
Date of registration:
|
11/12/2018 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Expanded Access to Mepsevii
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
March 29, 2019 |
|
Target sample size:
|
|
|
Recruitment status: |
Available |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT03775174 |
|
Study type:
|
Expanded Access |
|
Study design:
|
|
|
Phase:
|
|
|
|
Contacts
|
|
Name:
|
Early Access |
|
Address:
|
|
|
Telephone:
|
1-415-483-8800 |
|
Email:
|
EarlyAccess@ultragenyx.com |
|
Affiliation:
|
|
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
-
Exclusion Criteria:
-
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
MPS VII
|
|
Mucopolysaccharidosis VII
|
|
Sly Syndrome
|
|
Intervention(s)
|
|
Drug: Mepsevii
|
|
Secondary ID(s)
|
|
UX003-EAP
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|